Lipoprotein(a) Lowering Therapies Market

Antisense oligonucleotides lead the lipoprotein(a) lowering therapies market with a 41.1% share in 2026 by therapy type, followed by atherosclerotic cardiovascular disease at 34.2% by indication and hospitals at 33.2% by end user. Adoption reflects demand for targeted lipid-lowering therapies, while high development costs and clinical evidence requirements remain key constraints.